|
|
|
¾¾¹Ä·ºÆ®ÁÖ»ç(¹Ù½Ç¸¯½Ã¸¿) Simulect inj.
|
Àü¹®ÀǾàÇ° | ±Þ¿© | ½Å¾à
|
¼öÀÔÀǾàÇ°
|
|
|
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàÇ° ÀÎÅÍ³Ý ÆǸŸ¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
Àü¹®/ÀÏ¹Ý |
Àü¹®
|
|
|
¹«»ö ¹ÙÀ̾˿¡ ÃæÀüµÈ µ¿°á°ÇÁ¶ÇÑ ¹é»ö°¡·ç ¶Ç´Â µ¢¾î¸®. ¸ê±ÕÁÖ»ç¿ë¼ö·Î ³ì¿´À» ¶§ ¹«»ö ȤÀº À¯¹é±¤ÀÇ ¾×ÀÌ µÈ´Ù.
|
|
|
|
|
|
Á¦Á¶È¸»ç |
Novartis
|
ÆǸÅȸ»ç |
Çѱ¹³ë¹ÙƼ½º(ÁÖ)
|
Çã°¡Á¤º¸ |
Á¤»ó
(2004.12.22)
|
BIT ¾àÈ¿ºÐ·ù |
¸é¿ª¾ïÁ¦Á¦ (Immunosuppressants)
|
º¹ÁöºÎºÐ·ù |
142[ÀÚ°Ý¿ä¹ýÁ¦(ºñƯÀ̼º¸é¿ª¿øÁ¦Á¦¸¦ Æ÷ÇÔ) ] |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå |
653600671 \1,134,977 ¿ø/1º´(2024.07.01)(ÇöÀç¾à°¡)\1,144,720 ¿ø/1º´(2022.01.01) (º¯°æÀü¾à°¡)
|
|
|
ATCÄÚµå |
Basiliximab / L04AC02 |
NDCÄÚµå |
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
|
¼ººÐ / ÇÔ·® |
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
|
÷°¡Á¦ |
±Û¸®½Å,
¸¸´ÏÅç,
¹«¼öÀλê¼ö¼Ò³ªÆ®·ý,
¿°È³ªÆ®·ý,
ÀλêÀ̼ö¼ÒÄ®·ý,
ÀÚ´ç,
ÁÖ»ç¿ë¼ö
|
|
|
|
|
|
|
|
|
|
Ç× ¸ñ |
³» ¿ë |
|
ºÎÀÛ¿ëºóµµ ¹× ´ëó¹ý |
[À¯·á] |
|
|
|
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-06-28 |
|
|
|
|
|
|
|
|